Objective: To compare Brief Adlerian Psychodynamic Psychotherapy (B-APP) plus venlafaxine versus venlafaxine plus usual care on pain and depressive symptomatology of depressed patients with cancer pain.
Introduction :
In recent times, a growing number of epidemiological and clinical studies have shown the existence of complex relationships between cancer pain and mood disorders [1, 2] . The treatment of anxiety and depression in patients with pain is therefore a must:
basically, complete control of pain cannot be achieved without concomitant control of related emotional disturbances [3] . Depressive mood reduces the pain threshold and increases, emotionally and cognitively, the pain perception, while chronic pain induces depression. Similar biological mechanisms underlie both pathologies: first of all, a neurotransmitter reduction, mainly concerning serotonin (5HT) and norepinephrine (NE); secondly, a cytokine imbalance, with an increase of pro-inflammatory agents and a modification of neurotrophic factors, can intervene in such mutual involvement [4] .
Depression is the most prevalent psychological disorder among cancer patients and has a negative impact on quality of life and treatment adherence [5] .
A meta-analysis of studies that assessed pain in patients with cancer estimated its prevalence at 53%. [6, 7] .
Data suggest that the most effective treatment approaches to the treatment of depression and cancer pain include the combination of psychotherapeutic and pharmacological interventions [8, 9] . Antidepressants (ADs) demonstrate important effects on mood but also on pain. Serotonin and norepinephrine reuptake inhibitors (SNRIs such as venlafaxine, duloxetine, milnacipran) showed greater efficacy on painful physical symptoms of depression [10, 11] . Among SNRIs, venlafaxine shows peculiar pharmacodynamic and kinetic properties that suggest its use in oncological patients [12, 13] .
Consistent evidence supports the efficacy of psychological interventions for alleviating pain related to depression when added to pharmacological treatment.
Studies with varying results on the effects of Cognitive
Behavioural therapy (CBT) for cancer-related emotional distress and pain have been published [14, 15, 16] .
Psychotherapies can act by modifying pain intensity and the pain affective component [17, 18] . Conversely, only minimal data are available for psychological interventions other than Cognitive-Behavioural Therapy and, in particular, few studies have been carried out on psychodynamic psychotherapy [19] [20] [21] [22] . Moreover there are not any clinical trials on Brief-Adlerian Psychodynamic Psychotherapy (B-APP) applied to oncological patients with pain.
The main object of the study was to evaluate the effects of adding a psychotherapeutic intervention, Brief Adlerian Psychodynamic Psychotherapy (B-APP) to venlafaxine (VLF) related to pain and depressive symptoms compared with usual care plus venlafaxine on depressed oncological patients with pain.
Material and Methods :
This is a randomized, controlled trial comparing B-APP plus venlafaxine versus VLF plus usual care.
Randomization by a table of random number was centralized. Nine hundred and ninety five patients with cancer, of both sexes, from 18 to 75 years old, receiving ambulatory care at the Oncology Center of Citta'della Salute e della Scienza Hospital of Turin were screened for depression and pain. Table 1 .
Besides patients had to meet at least one of the two following criteria in order to be eligible for the study: 1) the fixed-dose opioid had to be at least an equianalgesic daily dose of 60 mg of oral morphine and the patients were not expected to gain further therapeutic benefit by further increasing of the dose of the opioid therapy; 2) they were experiencing or had previously experienced 
Interventions
The drug, that is in insurance, was dispensed by the clinicians involved in the study. Venlafaxine was started at the dose of 37,5 mg/day and increased to 75 mg/day after a week. The rationale of the starting low dose is according to the need of titration in oncological patients with pain [4, 23] . The choice of a fixed dose of 75 mg/day was related to a best balance between efficacy and tolerability in a group of frail patients with medium-high opioid dosages. Lorazepam 1-2 mg/day was allowed only during the first two weeks of treatment, in patients with anxiety and/or sleep disorders, and then was withdrawn.
The VLF group was subjected to a medical visit [24] . This technique has been described in a previous study [25] and has been used within a range of settings to treat various disorders [26] [27] [28] analysis. Cardinal variables were described by using the mean and standard deviation. The Paired-Samples t-Test was used to evaluate significant differences within each group between assessments at baseline (T0) and after 10 weeks (T1). Significant differences were calculated between COM and VLF groups by the IndependentSamples t-Test. As for ordinal variables, significant differences within each group between T0 and T1 were calculated using the Wilcoxon Signed Ranks Test;
whereas the Mann Whitney U Test was used to evaluate significant differences between the COM and VLF groups.
Results :
Of 995 patients consecutively evaluated in and one died at home because of the progression of oncological pathology.
The statistical analysis shows homogeneous demographic and clinical characteristics while the comparison between groups at T0 highlighted no significant difference on all rating scales.
Depression and anxiety symptoms
Mean self-evaluated HADS anxiety and depression scores decreased significantly in both treatment regimens during the 10 weeks of the study (Figure 1) . In both groups a significant difference of depression and anxiety symptoms between T0 and T1 was observed. The Independent Samples t-Test nevertheless showed a more significant improvement in the COM group than in the VLF group. (Table 2) .
Patient Satisfaction
At the end of the treatments, the total VSSS score, which quantifies the patients' satisfaction, was 
Efficacy and Safety Balance
First of all the Mann-Whitney U Test showed no differences at baseline between the two groups. The A further interesting finding of this study is that psychological treatment was associated with significant changes in measures of coping strategies [51] . Greater improvements were found in some subscales of the Mini These findings suggest that patients with an higher level of a sense of well-being, were more capable of confronting the reality of the situation and this implied that also most of the participants attempted to develop effective coping strategies in order to maintain their better psychosocial well-being [53] . Analyzing the VSSS-54, the subjects were satisfied with the treatment they had received as long as the intervention was effective. In particular, it was observed that brief psychotherapy, when associated with venlafaxine, showed greater improvements in prevention (p<0.01), social relations (p<0.01), working capacity (p<0.01) and self-care (p<0.01). In fact combined therapy, allows to confront the impact of pain on patients'social and existential concerns and to listen the needs of the patients, may be considered very relevant in determining their quality of life [54] .
Conclusion
This study provides data supporting the 
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